KURA (Kura Oncology) Change In Payables And Accrued Expense : $12.90 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Kura Oncology Change In Payables And Accrued Expense?

Kura Oncology's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $-5.43 Mil. It means Kura Oncology's Accounts Payable & Accrued Expense declined by $5.43 Mil from Dec. 2024 to Mar. 2025 .

Kura Oncology's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $15.20 Mil. It means Kura Oncology's Accounts Payable & Accrued Expense increased by $15.20 Mil from Dec. 2023 to Dec. 2024 .

Kura Oncology Change In Payables And Accrued Expense Historical Data

The historical data trend for Kura Oncology's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kura Oncology Change In Payables And Accrued Expense Chart

Kura Oncology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

5.68

-2.52

-0.80

10.33

15.20

Kura Oncology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-3.13	-0.05	5.68	12.70	-5.43

Kura Oncology Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.90 Mil.

Kura Oncology Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Kura Oncology's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Kura Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kura Oncology Inc (NAS:KURA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

KUR:Germany

Address

12730 High Bluff Drive, Suite 400, San Diego, CA, USA, 92130

Website

https://www.kuraoncology.com

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Executives

Teresa Brophy Bair	officer: Chief Legal Officer	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Kathleen Ford	officer: Chief Operating Officer	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Faheem Hasnain	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Brian T. Powl	officer: Chief Commercial Officer	C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Thomas James Doyle	officer: SVP, Finance & Accounting	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Stephen Dale	officer: Chief Medical Officer	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Troy Edward Wilson	director, officer: President and CEO	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thomas Malley	director	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Kirsten Flowers	officer: Chief Commercial Officer	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Helen Louise Collins	director	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Carol Schafer	director	42 WHITE STREET, FOURTH FLOOR, NEW YORK NY 10013
Marc Grasso	officer: CFO, CBO	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Bridget A Martell	officer: Acting Chief Medical Officer	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Basta	officer: Chief Legal Officer	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540